|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NTPCR |
Gene summary for NTPCR |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NTPCR | Gene ID | 84284 |
| Gene name | nucleoside-triphosphatase, cancer-related | |
| Gene Alias | C1orf57 | |
| Cytomap | 1q42.2 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q9BSD7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 84284 | NTPCR | LZE2T | Human | Esophagus | ESCC | 2.19e-02 | 9.18e-01 | 0.082 |
| 84284 | NTPCR | LZE4T | Human | Esophagus | ESCC | 1.78e-12 | 4.84e-01 | 0.0811 |
| 84284 | NTPCR | LZE7T | Human | Esophagus | ESCC | 1.01e-09 | 6.70e-01 | 0.0667 |
| 84284 | NTPCR | LZE8T | Human | Esophagus | ESCC | 5.69e-11 | 4.34e-01 | 0.067 |
| 84284 | NTPCR | LZE20T | Human | Esophagus | ESCC | 1.13e-07 | 1.55e-01 | 0.0662 |
| 84284 | NTPCR | LZE22D1 | Human | Esophagus | HGIN | 9.81e-03 | 1.75e-01 | 0.0595 |
| 84284 | NTPCR | LZE22T | Human | Esophagus | ESCC | 8.10e-05 | 3.74e-01 | 0.068 |
| 84284 | NTPCR | LZE24T | Human | Esophagus | ESCC | 1.19e-23 | 6.67e-01 | 0.0596 |
| 84284 | NTPCR | LZE21T | Human | Esophagus | ESCC | 7.82e-06 | 1.61e-01 | 0.0655 |
| 84284 | NTPCR | LZE6T | Human | Esophagus | ESCC | 6.11e-07 | 3.87e-01 | 0.0845 |
| 84284 | NTPCR | P1T-E | Human | Esophagus | ESCC | 5.14e-19 | 8.73e-01 | 0.0875 |
| 84284 | NTPCR | P2T-E | Human | Esophagus | ESCC | 2.05e-51 | 9.49e-01 | 0.1177 |
| 84284 | NTPCR | P4T-E | Human | Esophagus | ESCC | 5.65e-25 | 5.98e-01 | 0.1323 |
| 84284 | NTPCR | P5T-E | Human | Esophagus | ESCC | 7.68e-32 | 5.64e-01 | 0.1327 |
| 84284 | NTPCR | P8T-E | Human | Esophagus | ESCC | 4.57e-19 | 3.90e-01 | 0.0889 |
| 84284 | NTPCR | P9T-E | Human | Esophagus | ESCC | 2.27e-28 | 6.58e-01 | 0.1131 |
| 84284 | NTPCR | P10T-E | Human | Esophagus | ESCC | 6.56e-55 | 9.68e-01 | 0.116 |
| 84284 | NTPCR | P11T-E | Human | Esophagus | ESCC | 8.77e-19 | 8.75e-01 | 0.1426 |
| 84284 | NTPCR | P12T-E | Human | Esophagus | ESCC | 3.71e-29 | 5.58e-01 | 0.1122 |
| 84284 | NTPCR | P15T-E | Human | Esophagus | ESCC | 2.50e-29 | 6.74e-01 | 0.1149 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa012325 | Esophagus | ESCC | Nucleotide metabolism | 59/4205 | 85/8465 | 1.67e-04 | 6.58e-04 | 3.37e-04 | 59 |
| hsa0123212 | Esophagus | ESCC | Nucleotide metabolism | 59/4205 | 85/8465 | 1.67e-04 | 6.58e-04 | 3.37e-04 | 59 |
| hsa01232 | Liver | Cirrhotic | Nucleotide metabolism | 39/2530 | 85/8465 | 1.27e-03 | 6.73e-03 | 4.15e-03 | 39 |
| hsa012321 | Liver | Cirrhotic | Nucleotide metabolism | 39/2530 | 85/8465 | 1.27e-03 | 6.73e-03 | 4.15e-03 | 39 |
| hsa012322 | Liver | HCC | Nucleotide metabolism | 59/4020 | 85/8465 | 3.30e-05 | 1.88e-04 | 1.04e-04 | 59 |
| hsa012323 | Liver | HCC | Nucleotide metabolism | 59/4020 | 85/8465 | 3.30e-05 | 1.88e-04 | 1.04e-04 | 59 |
| hsa012324 | Oral cavity | OSCC | Nucleotide metabolism | 54/3704 | 85/8465 | 1.78e-04 | 5.95e-04 | 3.03e-04 | 54 |
| hsa0123211 | Oral cavity | OSCC | Nucleotide metabolism | 54/3704 | 85/8465 | 1.78e-04 | 5.95e-04 | 3.03e-04 | 54 |
| hsa0123221 | Oral cavity | LP | Nucleotide metabolism | 42/2418 | 85/8465 | 3.62e-05 | 2.36e-04 | 1.52e-04 | 42 |
| hsa0123231 | Oral cavity | LP | Nucleotide metabolism | 42/2418 | 85/8465 | 3.62e-05 | 2.36e-04 | 1.52e-04 | 42 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NTPCR | SNV | Missense_Mutation | novel | c.47C>A | p.Thr16Lys | p.T16K | Q9BSD7 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-A8-A09K-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| NTPCR | SNV | Missense_Mutation | rs758806446 | c.43A>G | p.Lys15Glu | p.K15E | Q9BSD7 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| NTPCR | SNV | Missense_Mutation | c.41G>C | p.Gly14Ala | p.G14A | Q9BSD7 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-IR-A3LL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| NTPCR | SNV | Missense_Mutation | rs148845457 | c.389G>A | p.Arg130His | p.R130H | Q9BSD7 | protein_coding | deleterious(0.05) | possibly_damaging(0.898) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| NTPCR | SNV | Missense_Mutation | c.283N>A | p.Val95Ile | p.V95I | Q9BSD7 | protein_coding | tolerated(0.27) | benign(0.038) | TCGA-AA-3966-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| NTPCR | SNV | Missense_Mutation | novel | c.151N>A | p.Asp51Asn | p.D51N | Q9BSD7 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| NTPCR | SNV | Missense_Mutation | rs759051611 | c.388N>T | p.Arg130Cys | p.R130C | Q9BSD7 | protein_coding | deleterious(0) | benign(0.226) | TCGA-A5-A0VP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| NTPCR | SNV | Missense_Mutation | rs759051611 | c.388C>T | p.Arg130Cys | p.R130C | Q9BSD7 | protein_coding | deleterious(0) | benign(0.226) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| NTPCR | SNV | Missense_Mutation | novel | c.130N>A | p.Gly44Arg | p.G44R | Q9BSD7 | protein_coding | tolerated(0.08) | benign(0.204) | TCGA-A5-A2K3-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | SD |
| NTPCR | SNV | Missense_Mutation | novel | c.290G>T | p.Arg97Met | p.R97M | Q9BSD7 | protein_coding | deleterious(0) | possibly_damaging(0.612) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |